MA42655A - Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer - Google Patents

Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer

Info

Publication number
MA42655A
MA42655A MA042655A MA42655A MA42655A MA 42655 A MA42655 A MA 42655A MA 042655 A MA042655 A MA 042655A MA 42655 A MA42655 A MA 42655A MA 42655 A MA42655 A MA 42655A
Authority
MA
Morocco
Prior art keywords
aminopyridin
methylpyrrolidine
benzofuran
fluorophenyl
fluoro
Prior art date
Application number
MA042655A
Other languages
English (en)
Inventor
Erkan Baloglu
William Senapedis
Sharon Shacham
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MA42655A publication Critical patent/MA42655A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA042655A 2015-08-18 2016-08-18 Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer MA42655A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562206472P 2015-08-18 2015-08-18

Publications (1)

Publication Number Publication Date
MA42655A true MA42655A (fr) 2021-04-07

Family

ID=56799634

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042655A MA42655A (fr) 2015-08-18 2016-08-18 Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer

Country Status (12)

Country Link
US (1) US10363247B2 (fr)
EP (1) EP3337797A1 (fr)
JP (1) JP2018528196A (fr)
CN (1) CN108137563A (fr)
AU (1) AU2016308829A1 (fr)
CA (1) CA2995380A1 (fr)
EA (1) EA201890524A1 (fr)
HK (1) HK1255438A1 (fr)
IL (1) IL257422A (fr)
MA (1) MA42655A (fr)
MX (1) MX2018001979A (fr)
WO (1) WO2017031323A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510339UA (en) * 2013-07-03 2016-01-28 Karyopharm Therapeutics Inc Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Composés multicycliques et leurs utilisations
CN111171233B (zh) * 2020-01-17 2023-03-31 吉林师范大学 一种新型磁性薄层印迹膜的制备方法及用途
CN115645396A (zh) * 2020-02-26 2023-01-31 上海科技大学 丙基-2-咪唑二硫醚在抗冠状病毒中的应用
CN114507215B (zh) * 2020-11-14 2024-09-13 成都海博为药业有限公司 一种作为pak4激酶抑制剂的化合物及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19818044A1 (de) 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
DE60216097T2 (de) 2001-07-19 2007-06-28 Pfizer Italia S.R.L. Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel
EP1348434A1 (fr) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Utilisation de pyridylamides comme inhibiteurs de l'angiogenèse
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7638540B2 (en) 2003-05-29 2009-12-29 The New Industry Research Organization Benzofuran compound and medicinal composition containing the same
US7420066B2 (en) 2003-08-07 2008-09-02 Bayer Pharmaceuticals Corporation Benzofuran derivatives useful for treating hyper-proliferative disorders
US7368476B2 (en) 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
KR101128065B1 (ko) 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
JPWO2006038606A1 (ja) 2004-10-05 2008-05-15 塩野義製薬株式会社 ビアリール誘導体
WO2006054793A1 (fr) 2004-11-19 2006-05-26 The New Industry Research Organization Dérivé de benzofurane et préparation pharmaceutique contenant ledit dérivé
CA2601983A1 (fr) 2005-04-06 2006-10-12 Astrazeneca Ab Heterocycles substitues et leur utilisation en tant qu'inhibiteurs de la chk1, de la pdk1 et de la pak
AR055916A1 (es) 2005-04-22 2007-09-12 Wyeth Corp Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
US20080020413A1 (en) 2006-03-29 2008-01-24 Columbia University Crystalline visfatin and methods therefor
WO2008026018A1 (fr) 2006-09-01 2008-03-06 Topotarget Switzerland Sa Nouveau procédé pour le traitement des maladies inflammatoires
EP2003118A1 (fr) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2
EP2197443A4 (fr) 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc Compositions et procédés pour influer sur les teneurs en nad+ en utilisant un inhibiteur de nicotinamide phosphoribosyle transférase
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
EP2098231A1 (fr) 2008-03-05 2009-09-09 Topotarget Switzerland SA Utilisation des inhibiteurs de la formation de NAD pour le traitement de lesions d'ischemie-reperfusion
FR2943669B1 (fr) 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US20130317027A1 (en) 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
CN103819393A (zh) 2010-03-01 2014-05-28 瑞科西有限公司 化合物及其治疗应用
BR112013028281A2 (pt) 2011-05-04 2017-01-10 Forma Tm Llc compostos e composições para inibição de nampt
JP2014518223A (ja) 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
WO2013082150A1 (fr) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Inhibiteurs à petite molécule de nicotinamide phosphoribosyltransférase (nampt)
WO2014074715A1 (fr) 2012-11-07 2014-05-15 Genentech, Inc. Dérivés d'amide cyclopropyle
WO2014085607A1 (fr) * 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Composés 2,3-dihydrobenzofuranyle substitués et leurs utilisations
WO2014111871A1 (fr) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited Dérivés de 4,5-dihydroisoxazole utilisés comme inhibiteurs de nampt
SG11201510339UA (en) * 2013-07-03 2016-01-28 Karyopharm Therapeutics Inc Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
EP3055304A1 (fr) 2013-10-09 2016-08-17 Eli Lilly and Company Nouveaux composés de pyridyloxyacétyl tétrahydroisoquinoline utiles en tant qu'inhibiteurs de nampt
WO2016100515A1 (fr) 2014-12-16 2016-06-23 Karyopharm Therapeutics Inc. Composés cycliques et leurs utilisations
MA42654A (fr) 2015-08-17 2018-06-27 Karyopharm Therapeutics Inc Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt
US20180244660A1 (en) 2015-08-17 2018-08-30 Karyopharm Therapeutics Inc. Cyclopropylderivatives and their use as kinase inhibitors
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Composés multicycliques et leurs utilisations
WO2017117406A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Benzofuranyles et benzoxazolyles substitués et leurs utilisations

Also Published As

Publication number Publication date
IL257422A (en) 2018-04-30
JP2018528196A (ja) 2018-09-27
US10363247B2 (en) 2019-07-30
MX2018001979A (es) 2019-04-25
EP3337797A1 (fr) 2018-06-27
CA2995380A1 (fr) 2017-02-23
AU2016308829A1 (en) 2018-03-08
WO2017031323A1 (fr) 2017-02-23
HK1255438A1 (zh) 2019-08-16
US20180235948A1 (en) 2018-08-23
EA201890524A1 (ru) 2018-07-31
CN108137563A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MA42655A (fr) Acrylamide de (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) pour le traitement du cancer
FR24C1026I1 (fr) Inhibiteurs de kras g12c
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
IL253945A0 (en) kdm1a inhibitors to treat the disease
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55694A (fr) Méthodes de conditionnement de patients pour la thérapie cellulaire t
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA41449A (fr) Polythérapies pour le traitement de cancers
IL279260A (en) KDM1A inhibitors for the treatment of diseases
DK3784103T3 (da) Gulvbehandlingsmaskine
MA45927A (fr) Vis pour implant dentaire
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
TR201909353T4 (tr) Multipl skleroz tedavisi.
IL259297A (en) Heterocyclic compounds for the treatment of disease
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
EP3749647C0 (fr) Dérivés de n-(5-(phényl)-1h-pyrazol-3-yl)-1h-indol-5-amine en tant qu'inhibiteurs tnik pour le traitement du cancer
MA42519A (fr) Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique
MA51688A (fr) Protéines prohémostatiques pour le traitement de saignement
MA49375A (fr) Composition pour le traitement de la blépharite
DK3515418T3 (da) Anvendelse af c-met-inhibitorer til behandling af cancere, der omfatter met-mutationer
FR3072015B1 (fr) Implant medical pour arthrodese
EP3529243C0 (fr) (z)-3-(2-(5-bromo-1h-indole-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile pour le traitement de l'endométriose